The global blood culture test market size was estimated at USD 3.2 billion in 2016. Escalating rate of approval for new products, including instruments and consumables for diagnosis of Bloodstream Infections (BSI), by regulatory authorities, is a major factor contributing to the growth of the market.
Blood culture tests play a vital role in the diagnosis of various infections such as bacterial, fungal, and mycobacterial. Various techniques, including conventional/manual and automated methods, are used by healthcare professionals for the detection of infection in the bloodstream. Thus, the demand for these tests is expected to rise in the near future.
U.S. blood culture test market, by technique, 2014 - 2025 (USD million)
Rising prevalence of infectious diseases, BSIs, and sepsis is expected to be the main factor driving the market growth. According to WHO, about 250,000 cases of BSIs occur annually in the U.S., and among them, around 80,000 patients in ICUs suffer from catheter-related BSIs. As a result, there is high demand for advanced test products by hospitals and clinical diagnostics laboratories for the detection of bacterial, fungal, and mycobacterial infections.
There has been an increase in R&D activities by many healthcare companies to develop advanced testing products such as instruments, consumables, and software. Investment in R&D for development of the novel product is a crucial strategy of vendors to support the long-term growth of their businesses. For instance, Becton, Dickinson and Company, a leading vendor, invested around USD 1,430 million in R&D in 2016.
Stringent government regulations for the development and manufacturing of diagnostic products, could hinder the growth of the market. The diagnostic products, such as instruments, kits, reagents, media, and assays, undergo rigorous clinical trials prior to a regulatory approval. This leads to a significant rise in the costs incurred by the manufacturers and delay in product launch. Commercialization of diagnostic products depends on successful completion of clinical trials, which is a long, uncertain, and costly process. In addition, the product recall is another major challenge faced by manufacturers, which could adversely affect the growth of the sector.
In 2016, the consumables segment was the largest revenue generating segment of the market. This is due to the large application of these products, such as blood culture media, assay, kits, and reagents, and other accessories, for diagnostics applications. In addition, repetitive purchase of consumables is another major driver that boosts the segment growth.
The instruments segment is expected to witness significant CAGR during the forecast period due to product advancements. The automated systems, incubators, colony counters, microscopes, and gram strainers are widely used for blood culture tests by hospitals and other diagnostic laboratories.
The diagnostics companies are focused on developing advance products to cater to the needs of their customers. For instance, in July 2014, bioMérieux, a leading diagnostics company, announced the CE mark attainment by its product VIRTUO-an advanced blood culture system for continuous monitoring of blood culture for microbial detection.
The demand for advanced blood culture testing products is high due to increasing prevalence of BSI and infectious diseases. Advanced automated systems provide fast results, minimize contamination risk, and deliver highly reliable results.
The prime techniques used for blood culture tests are conventional and automated techniques. The conventional technique was the highest revenue-grossing segment in 2016 due to its extensive use by hospitals, independent clinical laboratories, and pathology laboratories.
The automated technique segment is expected to showcase highest CAGR during the forecast period. This is due to the technological advancements, such as faster & precise results, and rising investments in R&D by manufacturers for new product development.
The companies are focused on launching advanced instruments and consumables to provide highly reliable and efficient tests to their customers. For instance, in June 2014, Becton, Dickinson and Company launched the BD BACTEC FX40 Blood Culture System along with the BD EpiCenter Microbiology Data Management System.
The U.S., Germany, France, the UK, China, Japan, and India are expected to account for high share of blood culture test market. Increasing prevalence of infectious diseases, local presence of a large number of diagnostics companies, and availability of a well-developed healthcare infrastructure are some of the factors that are anticipated to contribute to the industry growth.
Based on technology, the market is segmented into culture-based, molecular, and proteomic. The culture-based technology segment dominated the industry with the largest revenue share. This is due to high usage of this technology by hospital laboratories, reference laboratories, pathology laboratories, and physician office laboratories.
Molecular technology segment is expected to register the highest CAGR during the forecast period. Increasing investment in R&D by manufactures and increase in the incidence of infectious diseases has led to rise in demand for rapid diagnostic techniques for detecting the presence of bacterial or fungal infection in the blood.
The rising demand for advanced diagnostic technologies, such as microarray, Polymerase Chain Reaction (PCR), and Peptide Nucleic Acid - Fluorescent In Situ Hybridization (PNA-FISH), is expected to propel the industry growth. The PNA-FISH technology sub-segment is expected to grow at the highest CAGR during the forecast period owing to its advantages, such as higher accuracy, reduced test time, and higher specificity in tests.
Developing healthcare infrastructure and rising disposable income in Asia Pacific and MEA region have spurred the demand for blood culture tests. In addition, the increasing government initiatives to provide better quality healthcare facility coupled with easy availability advanced technologies is expected to boost the application of blood culture tests.
Blood culture tests are used to detect a bacterial infection that spreads into the blood in various conditions, such as osteomyelitis, meningitis, pneumonia, kidney infection, and sepsis. Fungal infection or mycobacterial infections can also be diagnosed with the help of these tests.
Bacterial infections segment dominated in terms of revenue in 2016. This is because the bacterial infection is the most common cause of BSI and other infections in the blood. The bacterial infections segment is also expected to grow at the highest CAGR during the forecast period.
This is due to increasing healthcare awareness and improving healthcare infrastructure in developing countries, such as South Africa, Tanzania, China, India, and Argentina, which is expected to propel the market growth. The governments of these countries are undertaking huge efforts to provide better quality healthcare facilities & diagnostic products, which further supports the adoption of blood culture test products.
The fungal infections segment is projected to witness lucrative growth over the study period owing to the prevalence of BSIs and rising number of sepsis cases worldwide. For instance, Candida species are predominant agents of fungal sepsis, which accounts for around 10% to 15% of healthcare-related infections.
The hospital laboratories accounted for the largest revenue share in the overall market. This is due to the increasing incidence of hospital-acquired infections. According to WHO, the rate of ICU-acquired infections, including urinary tract and surgical-site wound infections, is around two to three times higher in developing countries as compared to developed countries. In Canada, about 8,000 patients die annually because of hospital-acquired infections.
In addition, the hospital laboratories segment is expected to grow at the fastest CAGR over the forecast period. Rising healthcare awareness along with initiatives by the government and nongovernment organizations to prevent and control infectious diseases is the main factor responsible for the industry growth. For instance, CDC collaborated with the government of South Africa to develop national HIV clinical & research guidelines, support HIV & TB programs, and conduct epidemiology training.
UK blood culture test market share, by product, 2016 (%)
The reference laboratories segment is projected to have lucrative growth over the forecast period owing to increase in outsourcing of blood culture tests by hospitals to reference laboratories. The reference laboratories are equipped with novel and advanced diagnostic techniques, which provide more accurate, reliable, and fast result.
The other end-use segments are academic research laboratories, bacteriological laboratories, pathology laboratories, and physician office laboratories. This segment is also projected to grow at a significant rate during the forecast period.
Globally, the North America dominated with the largest revenue share due to the local presence of many large healthcare companies such as Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; and Roche Diagnostics.
Availability of advanced diagnostics products and presence of highly developed healthcare infrastructure in the European countries like Germany, the UK, Switzerland, and France have further fueled the growth of Europe blood culture tests market. Also, growing investments on R&D by manufactures for new product development in this region is expected to propel the growth of the industry.
Asia Pacific region is projected to witness highest CAGR during the forecast period due to the high prevalence of infectious diseases and developing healthcare infrastructure. There are many diagnostic companies that are targeting Asian countries, such as China and India, for business expansion. The presence of a large base of the target population and increasing disposable income in the Asia Pacific region are some of the key factors contributing to the growth of this region.
Some of the key players in the market are Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; Danaher Corporation; Luminex Corporation; Roche Diagnostics; Bruker Corporation; Abbott; and Alere. The major companies are undertaking various strategic initiatives including mergers & acquisitions, collaborations, new product development & launch, and regional expansions for serving the unmet needs of their customers.
The leading manufacturers such as Becton, Dickinson and Company; Roche Diagnostics, and Thermo Fisher Scientific, Inc. provide a broad range of advanced blood culture test products through their strong global distribution channel. It has led to intense competition amongst manufacturers, which is expected to affect the profit margin of vendors.
Mergers &acquisitions help the manufacturers to expand their existing product portfolio along with geographical reach. For instance, in June 2016, Luminex Corporation completed the acquisition of Nanosphere, Inc. to strengthen their molecular microbiology and diagnostics businesses.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, UK, Germany, Japan, India, China, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global blood culture test market on the basis of product, technique, technology, application, end-use, and region:
Product Outlook (Revenue, USD Million; 2014- 2025)
Blood culture media
Assay, kits, and reagents
Software & services
Technique Outlook (Revenue, USD Million; 2014 - 2025)
Technology Outlook (Revenue, USD Million; 2014 - 2025)
Application Outlook (Revenue, USD Million; 2014 - 2025)
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."